Technologies for Transfer – Archive 4

CALL FOR TECHNOLOGY TRANSFER – EXPRESSION OF INTEREST (EOI)

SCTIMST – BMT Wing is actively engaged in applied and translational research in areas of biomedical devices, biologics and biomaterials since late 1970s. The technologies developed indigenously by SCTIMST have been transferred to several industries, which have benefitted both the industry and society at large. Our record is marked with development of innovative and popular products such as the artificial heart valve ( TTK Healthcare Ltd), blood bags ( Peninsula polymers, now Terumo Penpol Ltd, HLL Lifecare Ltd), hydrocephalus shunt (HLL Lifecare Ltd), membrane oxygenator& cardiotomy reservoirs (SIDD Lifesciences Ltd), bio ceramic composites for dental and orthopedic applications ( Basic Healthcare Ltd, IFGL Refractories Ltd,), dental composites ( Anabond Stedmann Pharma Ltd), Intrauterine Device (HLL Lifecare Ltd), vein viewer (Agappe Diagnostics Ltd), Chitra Emergency Breathing Assist Device (Wipro enterprises pvt ltd) Multiplex RT PCR kit which targets two SARS COV2 genes RdRp and ORFb- nsp14 and the human RNAse gene as the internal control ( Huwel lifesciences pvt ltd), Chitra RNA isolation kit ( Agappe diagnostics ltd), Bone cement (Onyx medicals pvt ltd ) etc to name a few.

Also post Technology Transfer activities are ongoing for many more products like ASD occlusion device, flow diverter stent, LVAD,cholecyst derived scaffold for wound dressing applications, Diagnostic kit with antibiogram for Urinary Tract Infection (UTI), Tuberculosis screening device, PT/INR monitoring device, injectable hydrogel for cartilage repair, lint free absorbent wound dressing etc.

Last date : 12:00 noon on 15th February 2023

TECHNOLOGY TRANSFER – EXPRESSION OF INTEREST (EOI)

SCTIMST is offering technologies for licensing to enterprises including startups for further scaling up and commercialization. These technologies are available in different stages of readiness levels such as proof of concept, pre-clinical / clinical evaluation. The technologies can be licensed either on exclusive or non-exclusive basis against payment of a combination of up-front lumpsum fee and annual royalties, which will vary from product to product. Information on the technologies currently available for licensing may be viewed from the right side links.

Those interested are encouraged to contact Technology Business Division on phone - 0471-2520309/308 or email: tbd@sctimst.ac.in for further information or clarifications on the above and to facilitate visits and detailed discussions.

Interested parties may submit EoI proposals in the specified format(Annexure 1,2 & 3) indicating the technology/product of interest addressed to Head, BMT Wing, SCTIMST, Poojapura, Trivandrum-695012, latest by 12:00 noon on 15th February 2023 as signed hard copy.

Technology/Product Details

Intended end use

Point of care detection of Human papilloma virus using loop mediated amplification of DNA

Product description

Currently PAP smear is the initial test carried out for cervical cancer detection. This method has very low sensitivity. The technology developed by the Institute involves Loop mediated amplification (LAMP) based technique of nucleic acid for detecting HPV 16/18 types. The method has shown high specificity of detection for HPV types when tested in the research laboratory.

Current Development stage/ Evaluations done

The kit needs to be evaluated in clinical samples and for which discussions have been initiated with TATA Memorial Centre, Mumbai.

Industry responsibility

Involvement of industrial partner is required for clinical evaluation and further regulatory approvals followed by manufacturing

Deliverables from Institute

• Technology Transfer document with details on materials & consumables, SOPs, quality assurance.
• Data on the evaluations done

Option for co-development

Point of care detection of Human papilloma virus using RNA based technology is also under development. Industry interest is also invited for co-development on the same

2.   3D bioprinted skin tissue constructs

Intended end use

For research applications

Product description

Epidermal dermal construct with fibroblast and keratinocytes. Construct can be printed of different sizes with different layers of fibroblast and keratinocytes.

Novelty(please specify patents if any filed)

Two patent applications filed

Current Development stage/ Evaluations done

Bioink formulation was optimized and characterized. Seeding density, media composition culture conditions were optimized for skin construct. Construct can be printed in any shapes (square, circle, rectangle, triangle) Preliminary study on 24 rats were done.

Industry responsibility for technology transfer

Safety evaluation/toxicological evaluation. Absorb the technology and deliver to the researchers

Deliverables from Institute

• Technology Transfer document with details on materials & consumables, equipment & utilities, SOPs / detailed procedures. Quality assurance, handling properties.
• Training on the manufacture of the product
• Data on the evaluations done

3.   Universal airway device for isolation and selective ventilation of one lung

Figure 1: In vitro simulation of Universal Airway Device in a 3D printed adult trachea model a) Left lung collapse and right lung ventilation, b) Right lung collapse and left lung ventilation

Intended end use

For lung isolation and selective ventilation

Product description

The universal airway device is a single lumen endotracheal tube (ETT) incorporating a left ventilating eye that can be used along with a bronchial blocker for isolation and selective ventilation of one lung. The device has the following advantages: i) Unlike the predicate double lumen tube, which is larger in size, the proposed device is a single lumen tube with modification and can be used even in patients with difficult airway ii) Unlike conventional single lumen tube with bronchial blocker, the proposed device prevents displacement of bronchial blocker, once the blocker has been securely positioned.

Novelty(please specify patents if any filed)

Patent: One Indian Patent is filed.
Title: Universal airway device for lung isolation
File number: 202141019653, dated 29/04/2021

Certificate of Registration of Design granted
Design title: Universal Airway Device for Lung Isolation
Design no. 339436-001
Dated: 19/02/2021

Current Development stage/ Evaluations done

In vitro evaluation using human trachea model completed. in silico analysis (Ansys R18.2) was performed for visualizing the air flow during one lung ventilation using the device. Clinical evaluation to be undertaken with Industry collaboration.

Industry responsibility for technology transfer

In vivo evaluation, clinical evaluation, regulatory approvals and manufacturing (An industry having manufacturing facility of Endotracheal tubes is preferred)

Deliverables from Institute

• Technology Transfer document with details on materials & consumables, equipment & utilities, SOPs / detailed procedures. Quality assurance, handling properties.
• Training on the manufacture of the product
• Data on the evaluations done

4.   HRIDAY : Portable low cost disposable defibrillator for cardiac arrest management

Intended end use

HRIDAY defibrillator is low cost portable disposable defibrillator for the management of cardiac arrest victims for both Paediatric (50 joules) and Adult (150 joules)..It is mainly aiming to readily available in low cost via Ambulances,Taxis,small nursing homes, clinics, pharmacy for use

Product description

HRIDAY portable defibrillator is an external portable defibrillator for both Pediatric and Adult. Train of shocks can be delivered with the stored energy. The casing will have a facility to view the heart rhythm rhythm via small display. User need only to switch on the device and system will monitor the ECG of the patient connected via 3 lead ECG cables. User can select either Pediatric (50 Joule) or Adult (150 Joule) option by individual switches at a time Train of 6 shocks can be delivered and after each shocks system monitor the ECG and if patient revert back it can simply stop the shock process.

Technical Details:

• Biphasic Paediatric and Adult shock delivering through user friendly switching operations
• 2.4 TFT display for ECG monitoring.
• Charging time for 150 joules – Less than 7 seconds
• Biphasic wave of 10 milliseconds long
• Output voltage of 1700 V and 35 Ampere for 50 ohm body impedance.
• Portable, Pre-programmed with intelligence.
• Voice assisted shock delivery.
• Delivers a Train of 6 shock of 50/150 Biphasic joules once start Sense the cardiac rhythm after each shock. If reverted stops the remaining shocks.
• DC operated-Chargeable through keyed external adapter(Can be charged at recharging centre)
• Battery – 12.5 V, 1800 mAh
• Disposable paddles

Current Development stage/ Evaluations done

TRL -4
The proposed system undergoes various trials and safety test according to ISO 7010- E010 on the Division of Clinical Engineering of Sree Chitra Tirunal Institute of medical science and Technology (SCTIMST). The energy levels of both Adult and Pediatric discharged biphasic wave is analysed, the output waveform is validated with Digital Oscilloscope to confirm the Biphasic Truncated exponential with desired rise time and peak. Electrical safety validated through Electrical Safety Analyzer

Industry responsibility

Industry should ready to make the product as per safety and test standards suggesting the medical standards Commercial product which includes all the features of existing prototype and additionally some features like

• An intelligent system that detects heart arrhythmia and automatic discharge of shock if needed.
• Ultraportable size with low weight.
• Wireless operated patient monitoring and shock delivering system.
• Preclinical Evaluations
• Clinical trials
• Packaging
• Regulatory documentation and submissions

Deliverables from Institute

• Technology Transfer document with details on design, SOPs / detailed procedures, Quality assurance
• Data on the evaluations done so far